viewbit bio

Full interview: Bit bio developing a technology platform 'capable of producing any human cell type'

Bit bio's Mark Kotter speaks to Proactive London's Andrew Scott following the name change from Elpis Biomed.

The business has recently hired a number of industry heavy-hitters to its leadership team as it works towards its goal of developing a scalable platform technology capable of producing any human cell type.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of bit bio named herein, including the promotion by the Company of bit bio in any Content on the Site, the Company receives from said issuer...


Elpis BioMed applying its 'disruptive' technology to produce human cells at...

Mark Kotter, founder of Elpis BioMed Ltd, tells Proactive the company was spun-out of Cambridge University and is built around technology which allows you to produce human cells at scale. ''These are very important in the context of drug discovery, biomedical research and also cell...

on 27/7/18

2 min read